Reyon Pharmaceutical's Thrombin Prepares for U.S. Entry: Global Expansion of High-Margin Business

Reyon Pharmaceutical and Elisigen Jointly Present Successful Mid-Dose Clinical Data for 'NG101' at ASRS… Confirming Superior Low-Dose, High-Efficacy and Commercial Viability Over Competitors

Reyon Pharmaceutical’s Partner Elisigen to Deliver Oral Presentation on ‘NG101’ at ASRS 2026… “Standing Shoulder-to-Shoulder with Global Big Pharma”

Japanese Biotech Companies to Make Consecutive Visits to Reyon Pharmaceutical's Manufacturing Plant in July

Reyon Pharmaceutical Adds New Cash Cow, Launching Full-Scale Entry into the 300 Billion KRW Hemostatic Agent Market

Reyon Pharmaceutical: "Chemical Earning Power + Novel Drug Growth Potential… The Inaugural Year of Our Biopharmaceutical Leap"

High Expectations for NG101 as a Global Novel Drug, While Chemical Segment Defends Profitability

Reyon Pharmaceutical and Elisigen Present 52-Week Low-Dose Cohort Results for Co-Developed 'NG101' at ARVO 2026… "Proven Game Changer for Wet AMD Treatment"

Reyon Pharmaceutical Signs Term Sheet with Global Japanese Pharmaceutical Company for Thrombin Supply

Reyon Pharmaceutical Completes Registration in Japan for Superbug (MRSA) Antibiotic Supplied to Japanese Original Drug Developer